Preclinical and Clinical Safety and Efficacy of Faramir Treatment: A Novel Anti-Retroviral Drug 

Authors

  • Seyed Ahmad Seyed Alinaghi Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
  • Minoo Mohraz
  • Ebrahim Farzam
  • Hamid Reza Khorram Khorshid Genetic Research Center, University of Social welfare and Rehabilitation Sciences, Tehran, Iran
  • Koorosh Kamali Public Health Department, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran
  • Leila Sadeghi Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
  • Saeed Bayanolhagh
  • Fatemeh Golsoorat Pahlaviani

DOI:

https://doi.org/10.12970/2309-0529.2018.06.05

Keywords:

HIV, Faramir, Viral load, CD4 count.

Abstract

 Background: Alternative treatment is generally used from the first reporting of HIV/AIDS. Introduction of new herbal drugs with antiviral properties may be a significant contribution towards treating HIV-positive patients. This survey was thus conducted in order to evaluate preclinical toxicology, clinical safety and efficacy of Faramir.

References


[1] Florence E, Bottieau E, Lynen L, Colebunders R. Patients with HIV infection and fever: a diagnostic approach. Acta Clin Belg 2002; 57(4): 184-90. https://doi.org/10.1179/acb.2002.040
[2] Lehmann C, D'Angelo LJ. Human immunodeficiency virus infection in adolescents. Adolesc Med State Art Rev 2010; 21(2): 364-87, xi.
[3] Available from: http://www.unaids.org/en/resources/ documents/2014. Access Date: June 2015.
[4] Bertozzi S, Padian NS, Wegbreit J. Disease Control Priorities in Developing Countries. 2nd ed. Washington (DC): World Bank 2006.
[5] Harris W, Brown G. Antiretroviral agents used in the treatment of HIV infections. ABNF J 2001; 12(3): 67-9.
[6] Emadi Koochak H, Eskandari S, Najafi Z, et al. HIV Drug Resistance. In: SeyedAlinaghi SA, editor. Current Studies in HIV Research.1st ed. UAE: Bentham Science 2016; pp.180- 199. https://doi.org/10.2174/9781681082554116020016
[7] Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 2010; 17(1): 72-82. https://doi.org/10.1053/j.ackd.2009.07.009
[8] Farhoudi B. When to Start Antiretroviral Therapy. In: SeyedAlinaghi SA, editor. Current Studies in HIV Research.1st ed. UAE: Bentham Science 2016; pp. 151-165. https://doi.org/10.2174/9781681082554116020014
[9] Barbaro G. Pathogenesis of HIV-associated cardiovascular disease. Adv Cardiol 2003; 40: 49-70. https://doi.org/10.1159/000073175
[10] Sherer R, Dufla B, Ande4on R, et al. A phase 1B study of calanolide A in HIV-l-infected, anti-retroviral therapy in naive patients. 2000, 7th Con Retrovirus Opportunist Infec. San Francisco.
[11] Holodniy M, Koch J, Mistal M, et al. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol 1999; 94(11): 3267-73. https://doi.org/10.1111/j.1572-0241.1999.01535.x
[12] Paydary K, Emamzadeh-Fard S, Khoram Khorshid HR, Kamali K, SeyedAlinaghil SA, Mohraz M. Safety and Efficacy of Setarud (IMODTM) Among People Living with HIV/AIDS: A Review. Recent Patents on Anti-Infective Drug Discovery 2012; 7: 66-72. https://doi.org/10.2174/157489112799829756
[13] Mohraz M, Khairandish P, Kazerooni PA. A clinical trial on the efficacy of IMOD in AIDS patients. DARU Journal of Pharmaceutical Sciences 2009; 17(4): 277-284.
[14] Tshibangu KC, Worku ZB, de Jongh MA, van Wyk AE, Mokwena SO, Peranovic V. Assessment of effectiveness of traditional herbal medicine in managing HIV/AIDS patients in South Africa. East Afr Med J 2004; 81(10): 499-504. https://doi.org/10.4314/eamj.v81i10.9231
[15] Koffuor GA, Dickson R, Gbedema SY, Ekuadzi E, Dapaah G, Otoo LF. The immunostimulatory and antimicrobial property of two herbal decoctions used in the management of HIV/AIDS in Ghana. Afr J Tradit Complement Altern Med 2014; 11(3): 166-72. https://doi.org/10.4314/ajtcam.v11i3.24
[16] Burack JH, Cohen MR, Hahn JA, Abrams DI. Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996; 12(4): 386-393. https://doi.org/10.1097/00042560-199608010-00009
[17] Amon JJ. Dangerous medicines: Unproven AIDS cures and counterfeit anti-retroviral drugs. Global Health 2008; 4: 5. https://doi.org/10.1186/1744-8603-4-5
[18] Beck E, Miners A, Tolley K. The cost of HIV treatment and care; a global review. Pharmacoeconomics 2001; 19: 13-39. https://doi.org/10.2165/00019053-200119010-00002
[19] Sangkitporn L, Shide V, Klinbuayaem, et al. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients. Southeast Asian Journal of Tropical Medicine and Public Health 2005; 36(3): 704-708.
[20] Fellay J, Boubakr K, Ledergerber B, et al. Prevalence of adverse events associated with anti-retroviral treatment: Swiss HIV cohort study. Lancet 2001; 358: 1322-27. https://doi.org/10.1016/S0140-6736(01)06413-3
[21] Koiser O, Fellay J, Opravil M, et al. Adverse events to antiretroviral in the Swiss HIV cohort study: Effect in mortality and treatment modification. Antiviral Therapy 2007; 12: 1157- 64.
[22] Murphay RA, Sunpath H, Kuritzkes DR, Venter F, Gadhi RT. Anti-retroviral-therapy-associated toxicities in the resource poor world: the challenges of a limited formulary. J Inf Dis 2007; 196: S449-56. https://doi.org/10.1086/521112

Downloads

Published

2018-05-18

Issue

Vol. 6 No. 1 (2018)

Section

Articles